GO
Loading...

Enter multiple symbols separated by commas

Stocks Gilead Sciences Inc

More

  • NEW YORK— Drugmaker AbbVie Inc. reported better-than-expected second-quarter profit, but its sales disappointed Wall Street. The average estimate of eight analysts surveyed by Zacks Investment Research was for earnings of $1.06 per share. But, the results fell shy of Wall Street expectations, with five analysts surveyed by Zacks expecting $5.6 billion.

  • Your first trade for Tuesday Monday, 13 Jul 2015 | 6:32 PM ET

    The "Fast Money" traders give their final trades of the day.

  • 3 more picks from investor up 27% in ‘15 Tuesday, 7 Jul 2015 | 6:00 AM ET
    Monster Beverage

    Louis Navellier's "Squawk Box" Platinum Portfolio is already up 27 percent this year. Here are three of his favorite picks.

  • Your first trade for Wednesday Tuesday, 30 Jun 2015 | 6:21 PM ET

    The "Fast Money" traders give their final trades of the day.

  • Robertson: Euro could easily go below parity Tuesday, 30 Jun 2015 | 5:42 PM ET
    Tiger Management Advisors LLC CEO and co-founder Julian Robertson

    Greece itself isn't terribly important; the problem would be possible contagion if it exits the euro, hedge fund pioneer Julian Robertson said.

  • In their June 25 lawsuit, Yale University's Global Health Justice Partnership and the Treatment Action Group, an AIDS non-profit, said doctors and patients deserve more information about the "enormously costly" drugs Harvoni and Sovaldi to make informed decisions about whether to use them. The plaintiffs said Gilead ignored its request for the trial data,...

  • June 24- AbbVie Inc said on Wednesday that its hepatitis C cocktail Viekira Pak was effective whether or not it was used in combination with the compound ribavirin against the most common form of the disease, according to data from a late-stage study. All the patients in the study showed a sustained response to Viekira Pak as a standalone treatment after 12 weeks...

  • Biotech to break out, buy these names: Analyst Friday, 19 Jun 2015 | 3:19 PM ET
    Biotech research

    Biotech is going to break out, RBC Capital Markets' Michael Yee said. There are the names on his buy list.

  • Early movers: HSY, RHT, SWHC, STT, CAG & more Friday, 19 Jun 2015 | 7:50 AM ET
    Trader on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Gilead still has China patent for active compound. NEW YORK/ SHANGHAI, June 19- China has rejected a Gilead Sciences Inc patent application related to its costly hepatitis C drug, a U.S. advocacy group said, adding the move may lead to other countries to consider rejecting patents for the controversial treatment. Gilead, however, holds the China patent to the base...

  • June 19- China has rejected Gilead Sciences Inc's application for a new patent related to its costly hepatitis C drug Sovaldi, removing a potential barrier to generic versions of the drug there, a U.S. legal group announced on Friday. Gilead still has a patent in China on sofosbuvir, the main ingredient of Sovaldi, a highly effective treatment for hepatitis C which...

  • Portfolio Playbook: Buy the chips Thursday, 18 Jun 2015 | 3:23 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Portfolio Playbook: Buy the chips

  • Hedge funds top 2014 gain with these stocks Thursday, 18 Jun 2015 | 9:35 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Hedge fund returns in the first five months of the year have already surpassed the total for 2014. Here's how they're doing it.

  • NEW YORK, June 17- Tighter monetary policy typically dents a country's equity markets. "As long as inflation stays low, the sweet spot is in the equity market, particularly if the Fed is moving slowly," said Kathleen Gaffney, co-director of diversified fixed income and manager of the $1.8 billion Eaton Vance Bond Fund. Gaffney, whose fund is capped at 20 percent...

  • NEW YORK, June 17- Tighter monetary policy typically dents a country's equity markets. "As long as inflation stays low, the sweet spot is in the equity market, particularly if the Fed is moving slowly," said Kathleen Gaffney, co-director of diversified fixed income and manager of the $1.8 billion Eaton Vance Bond Fund. Gaffney, whose fund is capped at 20 percent...

  • Your drug prices too high? Here's who many blame Tuesday, 16 Jun 2015 | 3:00 AM ET
    Pharmaceuticals

    Americans place controlling drug costs at the top of their health-related concerns.

  • Cramer: Massive biotech moves that make sense Thursday, 11 Jun 2015 | 6:57 PM ET
    A worker prepares a flow cell slide for a genetic sequencing machine at a Regeneron Pharmaceuticals laboratory company's headquarters in Tarrytown, New York.

    Jim Cramer discusses the huge moves that the biotech stocks have made recently—do these moves make sense for your portfolio?

  • Which stocks seduce women vs. men Wednesday, 10 Jun 2015 | 10:03 AM ET
    Traders work on the floor of the New York Stock Exchange.

    You can see the demographic changes of stocks, as some are becoming more masculine, while others more feminine, according to data from SigFig.

  • 10 drugs to hit fed budget by $50B over decade Tuesday, 9 Jun 2015 | 1:42 PM ET
    Health Care

    Ten so-called breakthrough drugs for cancers and chronic conditions will cost taxpayers big bucks.

  • These are the best stocks from now to October Tuesday, 2 Jun 2015 | 10:56 AM ET
    Healthcare

    Since 1990 this stock sector has risen 5.2 percent. It's outperformed the broader market 65 percent of the time from May to October.